EMERGENT BIOSOLUTIONS INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
EMERGENT BIOSOLUTIONS INC. (EBS) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was -$700.00K.
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$200.00K.
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $100.00K.
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $0.00.
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$1.20M, a 340.00% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $500.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-01 | |||
| 2025-12-31 | $100.00K 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $100.00K 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$700.00K 10-Q · filed 2026-05-01 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$1.20M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$800.00K 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | -$200.00K 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $500.00K 10-K · filed 2025-03-04 | |||
| 2022-09-30 | -$600.00K 10-Q · filed 2023-12-11 | |||
| 2022-06-30 | $400.00K 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$300.00K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$300.00K 10-K · filed 2024-03-08 | |||
| 2021-09-30 | -$300.00K 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$100.00K 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | -$300.00K 10-Q · filed 2022-04-29 | |||
| 2020-12-31 | -$1.00M 10-K/A · filed 2023-12-11 | |||
| 2020-09-30 | -$500.00K 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | -$100.00K 10-Q · filed 2021-07-30 | |||
| 2020-03-31 | $100.00K 10-Q · filed 2021-04-30 | |||
| 2019-12-31 | $400.00K 10-K · filed 2022-02-25 | |||
| 2019-09-30 | -$100.00K 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-01 | |||
| 2018-12-31 | -$200.00K 10-K · filed 2021-02-19 | |||
| 2018-09-30 | -$600.00K 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | -$100.00K 10-Q · filed 2019-08-02 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |